SELLAS Life Sciences (SLS) Invested Capital (2010 - 2026)
SELLAS Life Sciences (SLS) reported Invested Capital of $107.4 million for Q1 2026, up 286.94% year-over-year from $27.8 million in Q1 2025, and up 51.56% on a QoQ basis from $70.9 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Invested Capital data on file, last reported at $107.4 million in Q1 2026.
- Quarterly Invested Capital rose 286.94% year-over-year to $107.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.4 million (up 286.94% YoY) and the FY2025 annual result came in at $70.9 million, up 648.77% from the prior year.
- Invested Capital climbed to $107.4 million in Q1 2026 per SLS's latest filing, from $70.9 million in the prior quarter.
- Across five years, Invested Capital topped out at $107.4 million in Q1 2026 and bottomed at -$8.0 million in Q4 2023.
- The 5-year median for Invested Capital is $12.6 million (2022), against an average of $21.3 million.
- The widest annual swing landed in 2023, when Invested Capital sank 264.42%; it then surged 797.67% in 2025.
- Tracing SLS's Invested Capital over 5 years: stood at $4.9 million in 2022, then slumped by 264.42% to -$8.0 million in 2023, then jumped by 218.67% to $9.5 million in 2024, then soared by 648.77% to $70.9 million in 2025, then soared by 51.56% to $107.4 million in 2026.
- Per Business Quant, the three latest SLS Invested Capital figures stand at $107.4 million (Q1 2026), $70.9 million (Q4 2025), and $45.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 107.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.41 Mn |
| Dec 31, 2025 | 70.87 Mn |
| Sep 30, 2025 | 45.63 Mn |
| Jun 30, 2025 | 26.15 Mn |
| Mar 31, 2025 | 27.76 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 15.89 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Dec 31, 2023 | -7.98 Mn |
| Sep 30, 2023 | -3.83 Mn |
| Jun 30, 2023 | 4.84 Mn |
| Mar 31, 2023 | 13.17 Mn |
| Dec 31, 2022 | 4.85 Mn |
| Sep 30, 2022 | 12.60 Mn |
| Jun 30, 2022 | 19.06 Mn |
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 20.35 Mn |
| Sep 30, 2021 | 26.61 Mn |
| Jun 30, 2021 | 33.42 Mn |
| Mar 31, 2021 | 28.74 Mn |
| Dec 31, 2020 | 27.96 Mn |
| Sep 30, 2020 | 7.95 Mn |
| Jun 30, 2020 | 3.78 Mn |
| Mar 31, 2020 | 8.06 Mn |
| Dec 31, 2019 | 6.09 Mn |
| Sep 30, 2019 | 10.64 Mn |
| Jun 30, 2019 | 14.34 Mn |
| Mar 31, 2019 | 2.95 Mn |
| Dec 31, 2018 | 5.25 Mn |
| Sep 30, 2018 | 18.56 Mn |
| Jun 30, 2018 | 5.32 Mn |
| Mar 31, 2018 | 8.38 Mn |
| Dec 31, 2017 | 10.45 Mn |
| Sep 30, 2017 | 26.81 Mn |
| Jun 30, 2017 | 32.15 Mn |
| Mar 31, 2017 | 39.79 Mn |
| Dec 31, 2016 | -3.29 Mn |
| Sep 30, 2016 | 47.65 Mn |
| Jun 30, 2016 | 43.48 Mn |
| Mar 31, 2016 | 16.15 Mn |
| Dec 31, 2015 | -7.52 Mn |
| Sep 30, 2015 | 36.58 Mn |
| Jun 30, 2015 | 53.44 Mn |
| Mar 31, 2015 | 63.08 Mn |
| Dec 31, 2014 | 45.22 Mn |
| Sep 30, 2014 | 35.02 Mn |
| Jun 30, 2014 | 32.39 Mn |
| Mar 31, 2014 | 49.61 Mn |
| Dec 31, 2013 | 15.89 Mn |
| Sep 30, 2013 | 35.84 Mn |
| Jun 30, 2013 | 15.53 Mn |
| Mar 31, 2013 | 23.31 Mn |
| Dec 31, 2012 | 27.76 Mn |
| Sep 30, 2012 | 14.17 Mn |
| Mar 31, 2012 | -10.57 Mn |
| Dec 31, 2011 | 10.11 Mn |
| Sep 30, 2011 | 4.71 Mn |
| Jun 30, 2011 | 7.13 Mn |
| Dec 31, 2010 | -55.74 Mn |